Patents by Inventor Caetano Reis E Sousa

Caetano Reis E Sousa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYTOSOLIC DELIVERY
    Publication number: 20240100161
    Abstract: The present invention relates to chimeric receptors capable of facilitating cross-presentation (XP) of antigens, and methods of doing the same.
    Type: Application
    Filed: July 30, 2021
    Publication date: March 28, 2024
    Inventors: Caetano REIS E SOUSA, Johnathan Anias CANTON, Conor Maurice HENRY, Hanna BLEES
  • IMMUNOTHERAPY
    Publication number: 20230357388
    Abstract: Gelsolin inhibitors are provided for use in treating diseases such as infectious diseases and cancer. Prognostic methods and methods for screening for gelsolin inhibitors are also provided.
    Type: Application
    Filed: September 24, 2021
    Publication date: November 9, 2023
    Inventors: Caetano REIS E SOUSA, Evangelos GIAMPAZOLIAS, Oliver SCHULZ, Naren SRINIVASAN, Oliver GORDON, Probir CHAKRAVARTY
  • Immune modulation via C-type lectin
    Patent number: 9205153
    Abstract: The invention relates to the regulation of the immune system, and in particular to the finding that the CLEC9a molecule is a marker for dendritic cells which are capable of cross-presenting extracellular antigens via the MHC class I pathway. This makes them particularly suitable for generation of cytotoxic T lymphocyte responses. Materials and methods are provided both for the induction of immune responses against target antigens, and for the inhibition or suppression of undesirable immune responses in which these cells are involved.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: December 8, 2015
    Assignee: Cancer Research Technology Limited
    Inventors: David Sancho-Madrid, Oliver Schulz, Neil Charles Rogers, Caetano Reis e Sousa, Olivier Pierre Joffre, Daniel Pennington
  • Immune Modulation Via C-Type Lectin
    Publication number: 20140328865
    Abstract: The invention relates to the regulation of the immune system, and in particular to the finding that the CLEC9a molecule is a marker for dendritic cells which are capable of cross-presenting extracellular antigens via the MHC class I pathway. This makes them particularly suitable for generation of cytotoxic T lymphocyte responses. Materials and methods are provided both for the induction of immune responses against target antigens, and for the inhibition or suppression of undesirable immune responses in which these cells are involved.
    Type: Application
    Filed: October 9, 2013
    Publication date: November 6, 2014
    Applicant: Cancer Research Technology Limited
    Inventors: David Sancho-Madrid, Oliver Schulz, Neil Charles Rogers, Caetano Reis e Sousa, Olivier Pierre Joffre, Daniel Pennington
  • Immune modulation via C-type lectin
    Patent number: 8580266
    Abstract: The invention relates to the regulation of the immune system, and in particular to the finding that the CLEC9a molecule is a marker for dendritic cells which are capable of cross-presenting extracellular antigens via the MHC class I pathway. This makes them particularly suitable for generation of cytotoxic T lymphocyte responses. Materials and methods are provided both for the induction of immune responses against target antigens, and for the inhibition or suppression of undesirable immune responses in which these cells are involved.
    Type: Grant
    Filed: July 21, 2008
    Date of Patent: November 12, 2013
    Assignee: Cancer Research Technology Limited
    Inventors: David Sancho-Madrid, Oliver Schulz, Neil Charles Rogers, Caetano Reis E Sousa, Olivier Pierre Joffre, Daniel Pennington
  • IMMUNE MODULATION VIA C-TYPE LECTIN
    Publication number: 20100221265
    Abstract: The invention relates to the regulation of the immune system, and in particular to the finding that the CLEC9a molecule is a marker for dendritic cells which are capable of cross-presenting extracellular antigens via the MHC class I pathway. This makes them particularly suitable for generation of cytotoxic T lymphocyte responses. Materials and methods are provided both for the induction of immune responses against target antigens, and for the inhibition or suppression of undesirable immune responses in which these cells are involved.
    Type: Application
    Filed: July 21, 2008
    Publication date: September 2, 2010
    Inventors: David Sancho-Madrid, Oliver Schulz, Neil Charles Rogers, Caetano Reis E. Sousa, Olivier Pierre Joffre, Daniel Pennington
  • METHODS AND COMPOSITIONS FOR TREATING IMMUNE DISORDERS
    Publication number: 20090169472
    Abstract: The present invention provides oligonucleotides, compositions comprising them and methods that use the oligonucleotides and compositions for stimulating cells expressing the TLR7 and/or TLR8 receptor. The oligonucleotides comprise for stimulating TLR7 comprise uracil-rich regions. The oligonucleotides for stimulating TLR8 comprise guanine-rich regions. The present methods and compositions are useful, inter alia, for treating or preventing conditions such as infectious disease and cancer.
    Type: Application
    Filed: October 12, 2006
    Publication date: July 2, 2009
    Applicant: CANCER RESEARCH TECHNOLOGY LTD.
    Inventors: Sandra Diebold, Caetano Reis E Sousa, Carine Paturel